Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EBT (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed EBT for 7 consecutive years, with -$20.3 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 22.73% to -$20.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$74.9 million, a 21.51% increase, with the full-year FY2025 number at -$74.9 million, down 669.97% from a year prior.
  • EBT was -$20.3 million for Q4 2025 at Fulcrum Therapeutics, down from -$19.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$16.6 million in Q4 2024 to a low of -$34.1 million in Q2 2022.
  • A 5-year average of -$22.2 million and a median of -$20.5 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 73.4% in 2022, then surged 34.29% in 2025.
  • Fulcrum Therapeutics' EBT stood at -$23.5 million in 2021, then crashed by 45.08% to -$34.1 million in 2022, then rose by 29.51% to -$24.0 million in 2023, then skyrocketed by 31.02% to -$16.6 million in 2024, then dropped by 22.73% to -$20.3 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's EBT are -$20.3 million (Q4 2025), -$19.6 million (Q3 2025), and -$17.3 million (Q2 2025).